| Literature DB >> 35770151 |
N A Velázquez-Ulloa1, M E Heres-Pulido2, L F Santos-Cruz2, A Durán-Díaz3, L Castañeda-Partida2, A Browning1, C Carmona-Alvarado2, J C Estrada-Guzmán2, G Ferderer1, M Garfias1,4, B Gómez-Loza2, M J Magaña-Acosta2,5, H H Perry1, I E Dueñas-García2.
Abstract
Nicotine (NIC) and resveratrol (RES) are chemicals in tobacco and wine, respectively, that are widely consumed concurrently worldwide. NIC is an alkaloid known to be toxic, addictive and to produce oxidative stress, while RES is thought of as an antioxidant with putative health benefits. Oxidative stress can induce genotoxic damage, yet few studies have examined whether NIC is genotoxic in vivo. In vitro studies have shown that RES can ameliorate deleterious effects of NIC. However, RES has been reported to have both antioxidant and pro-oxidant effects, and an in vivo study reported that 0.011 mM RES was genotoxic. We used the Drosophila melanogaster wing spot test to determine whether NIC and RES, first individually and then in combination, were genotoxic and/or altered the cell division. We hypothesized that RES would modulate NIC's effects. NIC was genotoxic in the standard (ST) cross in a concentration-independent manner, but not genotoxic in the high bioactivation (HB) cross. RES was not genotoxic in either the ST or HB cross at the concentrations tested. We discovered a complex interaction between NIC and RES. Depending on concentration, RES was protective of NIC's genotoxic damage, RES had no interaction with NIC, or RES had an additive or synergistic effect, increasing NIC's genotoxic damage. Most NIC, RES, and NIC/RES combinations tested altered the cell division in the ST and HB crosses. Because we used the ST and HB crosses, we demonstrated that genotoxicity and cell division alterations were modulated by the xenobiotic metabolism. These results provide evidence of NIC's genotoxicity in vivo at specific concentrations. Moreover, NIC's genotoxicity can be modulated by its interaction with RES in a complex manner, in which their interaction can lead to either increasing NIC's damage or protecting against it.Entities:
Keywords: Drosophila wing spot test; Genotoxic damage; Nicotine; Resveratrol; Xenobiotic metabolism
Year: 2022 PMID: 35770151 PMCID: PMC9234589 DOI: 10.1016/j.heliyon.2022.e09744
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Summary of results obtained in the standard (ST) and high bioactivation (HB) crosses of the Drosophila wing SMART after scoring marker-heterozygous flies (mwh +/+ flr, wild-type wings) treated with resveratrol (RES) at [0.0, 0.0004, 0.011 mM]; Milli-Q water and ethanol 1% as dissolvent controls.
| Compound Cross | Type | Number of flies | Spots per Fly (Number of Spots) Statistical Diagnosis | Mean | Clone formation | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Small single spots | large single spots | Twin spots | Total spots | per 105 per cell | cells division | |||||
| (1-2 cells) | (>2 cells) | observed | control connected | |||||||
| m = 2 | m = 5 | m = 5 | m = 5 | |||||||
| ST | ||||||||||
| #1 Assay | ||||||||||
| Dissolvent control | ||||||||||
| Water | 51 | 0.47 (024) | 0.10 (005) | 0.00 (000) | 0.57 (029) | 29 | 1.69 | 1.25 | ||
| EtOH | 1 % | 57 | 0.39 (022) - | 0.09 (005) - | 0.00 (000) - | 0.47 (027) - | 27 | 1.81 | 0.95 | -0.25 |
| RES treatments | ||||||||||
| EtOH | 1 % | 57 | 0.39 (022) | 0.09 (005) | 0.00 (000) | 0.47 (027) | 27 | 1.81 | 0.95 | |
| RES | 0.0004 | 58 | 0.53 (031) - | 0.07 (004) - | 0.00 (000) - | 0.60 (035) - | 33 | 1.64 | 1.15 | 0.20 |
| RES | 0.0110 | 58 | 0.47 (027) - | 0.03 (002) - | 0.07 (004) + | 0.57 (033) - | 32 | 1.84 | 1.15 | 0.20 |
| #2 Assay | ||||||||||
| Dissolvent control | ||||||||||
| Water | 61 | 0.46 (028) | 0.07 (004) | 0.02 (001) | 0.54 (033) | 33 | 1.70 | 1.1 | ||
| EtOH | 1 % | 60 | 0.45 (027) - | 0.15 (009) - | 0.05 (003) - | 0.65 (039) - | 38 | 2.34 | 1.3 | 0.20 |
| RES treatment | ||||||||||
| EtOH | 1 % | 60 | 0.45 (027) | 0.15 (009) | 0.05 (003) | 0.65 (039) | 38 | 2.34 | 1.30 | |
| RES | 0.0110 | 99 | 0.58 (057) - | 0.05 (005) - | 0.04 (004) - | 0.67 (066) - | 65 | 1.58 | 1.35 | 0.05 |
| HB | ||||||||||
| #1 Assay | ||||||||||
| Dissolvent control | ||||||||||
| Water | 35 | 0.54 (019) | 0.06 (002) | 0.00 (000) | 0.60 (021) | 21 | 1.29 | 1.25 | ||
| EtOH | 1 % | 35 | 0.34 (012) - | 0.09 (003) - | 0.03 (001) - | 0.46 (016) - | 16 | 1.94 | 0.95 | -0.3 |
| RES treatment | ||||||||||
| EtOH | 1 % | 35 | 0.34 (012) | 0.09 (003) | 0.03 (001) | 0.46 (016) | 16 | 1.94 | 0.95 | |
| RES | 0.0004 | 87 | 0.52 (045) - | 0.06 (005) - | 0.01 (001) - | 0.59 (051) - | 51 | 1.84 | 1.20 | 0.25 |
| #2 Assay | ||||||||||
| Dissolvent control | ||||||||||
| Water | 61 | 0.66 (040) | 0.07 (004) | 0.00 (000) | 0.72 (044) | 44 | 1.43 | 1.5 | ||
| EtOH | 1 % | 60 | 0.60 (036) - | 0.08 (005) - | 0.00 (000) - | 0.68 (041) - | 40 | 1.37 | 1.35 | -0.15 |
| RES treatment | ||||||||||
| EtOH | 1 % | 60 | 0.60 (036) | 0.08 (005) | 0.00 (000) | 0.68 (041) | 40 | 1.37 | 1.35 | |
| RES | 0.0110 | 60 | 0.73 (044) - | 0.07 (004) - | 0.02 (001) - | 0.82 (049) - | 48 | 1.56 | 1.65 | 0.25 |
| #3 Assay | ||||||||||
| Dissolvent control | ||||||||||
| Water | 50 | 0.50 (025) | 0.10 (005) | 0.04 (002) | 0.64 (032) | 32 | 1.66 | 1.30 | ||
| EtOH | 1 % | 60 | 0.33 (020) - | 0.17 (010) - | 0.00 (000) - | 0.50 (030) - | 28 | 2.00 | 0.95 | -0.35 |
| RES treatment | ||||||||||
| EtOH | 1 % | 60 | 0.33 (020) | 0.17 (010) | 0.00 (000) | 0.50 (030) | 28 | 2.00 | 0.95 | |
| RES | 0.0110 | 59 | 0.36 (021) - | 0.02 (001) ↓ | 0.02 (001) - | 0.39 (023) - | 23 | 1.43 | 0.80 | -0.15 |
Statistical diagnoses according to Frei and Würgler (1988) m: minimal risk multiplication factor for the assessment of negative results. For the final statistical diagnosis of all positive (+) and negative (-) results; (↓) significant decrease; the non-parametric Mann-Whitney and Wilcoxon U-test with significance levels α and β = 0.05 was used to exclude false positive or negative diagnoses [Frei and Würgler, 1995]. One side binomial test, significance levels α and β: significative results: + (α ≤ 0.05; no significant results: - (β ≤ 0.05).
ST: standard cross; HB: high bioactivation cross.
Clone frequencies per fly divided by the number of cells examined per fly (48,800) gives an estimate of formation frequencies per cell and per cell division in chronic exposure experiments [Frei and Würgler, 1995].
Statistical comparisons between Nicotine, Resveratrol vs. dissolvent controlsa or co-treatmentsb of the accumulated mwh clones size class distribution in ST and HB crossesc.
| Control | Treatment | Diagnosis | |
|---|---|---|---|
| ST cross | HB cross | ||
| Water | Ethanol 1 | - | i |
| Water | Nicotine 0.0125 | + | - |
| Nicotine 0.025 | + | + | |
| Nicotine 0.050 | + | + | |
| Nicotine 0.456 | - | + | |
| Nicotine 1.9 | - | i | |
| Nicotine 3.8 | + | + | |
| Nicotine 11.4 | + | ||
| Ethanol 1 | Resveratrol 0.0004 | + | + |
| Resveratrol 0.011 | + | i | |
| Ethanol 1 | Nicotine 0.456 + RES 0.0004 mM | + | + |
| Nicotine 1.9 + RES 0.0004 mM | + | - | |
| Nicotine 3.8 + RES 0.0004 mM | + | + | |
| Nicotine 11.4 + RES 0.0004 mM | + | + | |
| Ethanol 1 | Nicotine 0.0125 + RES 0.011 mM | + | + |
| Nicotine 0.025 + RES 0.011 mM | + | - | |
| Nicotine 0.050 + RES 0.011 mM | - | - | |
| Nicotine 0.456 + RES 0.011 mM | + | + | |
| Nicotine 1.9 + RES 0.011 mM | + | - | |
| Nicotine 3.8 + RES 0.011 mM | + | + | |
| Nicotine 11.4 + RES 0.011 mM | + | ||
| RES 0.0004 mM | Nicotine 0.456 + RES 0.0004 mM | + | + |
| Nicotine 1.9 + RES 0.0004 mM | + | + | |
| Nicotine 3.8 + RES 0.0004 mM | + | - | |
| Nicotine 11.4 + RES 0.0004 mM | + | + | |
| RES 0.011 mM | Nicotine 0.0125 + RES 0.011 mM | + | + |
| Nicotine 0.025 + RES 0.011 mM | - | + | |
| Nicotine 0.050 + RES 0.011 mM | + | + | |
| Nicotine 0.456 + RES 0.011 mM | + | - | |
| Nicotine 1.9 + RES 0.011 mM | + | - | |
| Nicotine 3.8 + RES 0.011 mM | + | + | |
| Nicotine 11.4 + RES 0.011 mM | + | ||
| Nicotine 0.456 | Nicotine 0.456 + RES 0.0004 mM | + | + |
| Nicotine 1.9 | Nicotine 1.9 + RES 0.0004 mM | + | + |
| Nicotine 3.8 | Nicotine 3.8 + RES 0.0004 mM | + | + |
| Nicotine 11.4 | Nicotine 11.4 + RES 0.0004 mM | + | |
| Nicotine 0.0125 | Nicotine 0.0125 + RES 0.011 mM | + | + |
| Nicotine 0.025 | Nicotine 0.025 + RES 0.011 mM | + | + |
| Nicotine 0.050 | Nicotine 0.050 + RES 0.011 mM | + | + |
| Nicotine 0.456 | Nicotine 0.456 + RES 0.011 mM | + | - |
| Nicotine 1.9 | Nicotine 1.9 + RES 0.011 mM | + | i |
| Nicotine 3.8 | Nicotine 3.8 + RES 0.011 mM | + | + |
| Nicotine 11.4 | Nicotine 11.4 + RES 0.011 mM | + | |
cKolmogorov–Smirnov test was performed to statistically analyze the accumulated mwh clones size class distribution in each treatment or co-treatment against the corresponding control (P < 0.05); positive (+) results indicate statistical significant alteration of the cell division on imaginal wing cells, therefore, there are cytotoxic effects (Santos-Cruz et al., 2020; Graf et al., 1984); negative (-) results signify that P > 0.05; (☠) signifies that treatment or co-treatment was lethal with no survivors; (i) signifies “inconclusive” which we use to denote cases when two or more independent tests were conducted and statistical results did not coincide.
. Summary of results obtained in the standard (ST) and high bioactivation (HB) crosses of the Drosophila wing SMART after scoring marker-heterozygous flies (mwh +/+ flr, wild-type wings) treated with nicotine (NIC) at [0, 0.0125, 0.025, 0.05, 0.456, 1.9, 3.8, 11.4 mM]; urethane (URE)[20 mM] and Milli-Q water as positive and dissolvent controls, respectively.
| Compound Cross | Number of flies | Spots per Fly (Number of Spots) Statistical Diagnosis | Mean | Clone formation | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Type | Small single spots | large single spots | Twin spots | Total spots | per 105 per cell | cells division | ||||
| (1-2 cells) | (>2 cells) | observed | control connected | |||||||
| m = 2 | m = 5 | m = 5 | m = 5 | |||||||
| ST | ||||||||||
| Positive control | ||||||||||
| Water | 61 | 0.46 (28) | 0.07 (04) | 0.02 (1) | 0.54 (33) | 33 | 1.70 | 1.10 | ||
| URE | 20.0 | 28 | 1.21 (34) + | 0.11 (03) - | 0.04 (1) - | 1.36 (38) + | 38 | 1.45 | 2.80 | 1.65 |
| NIC treatments | ||||||||||
| Water | 0 | 61 | 0.46 (28) | 0.07 (04) | 0.02 (1) | 0.54 (33) | 33 | 1.70 | 1.10 | |
| NIC | 0.0125 | 44 | 1.16 (51) + | 0.43 (19) - | 0.00 (0) - | 1.59 (70) + | 70 | 2.26 | 3.25 | 2.15 |
| NIC | 0.0250 | 41 | 0.66 (27) - | 0.00 (00) - | 0.02 (1) - | 0.68 (28) - | 28 | 1.21 | 1.40 | 0.30 |
| NIC | 0.0500 | 21 | 0.67 (14) - | 0.10 (02) - | 0.05 (1) - | 0.81 (17) - | 17 | 1.47 | 1.65 | 0.55 |
| Water | 0 | 51 | 0.47 (24) - | 0.10 (05) | 0.00 (0) | 0.57 (29) | 29 | 1.69 | 1.15 | |
| NIC | 0.4560 | 38 | 0.68 (26) - | 0.05 (02) - | 0.00 (0) - | 0.74 (28) - | 28 | 1.54 | 1.50 | 0.35 |
| NIC | 1.9000 | 46 | 0.57 (26) - | 0.04 (02) - | 0.02 (1) - | 0.63 (29) - | 28 | 1.57 | 1.25 | 0.10 |
| NIC | 3.8000 | 32 | 0.62 (20) - | 0.03 (01) - | 0.03 (1) - | 0.69 (22) - | 22 | 1.45 | 1.40 | 0.25 |
| NIC | 11.4000 | 22 | 1.27 (28) + | 0.23 (05) - | 0.05 (1) - | 1.55 (34) + | 34 | 1.71 | 3.15 | 2.00 |
| HB | ||||||||||
| Positive control | ||||||||||
| Water | 0 | 61 | 0.66 (40) | 0.07 (04) | 0.00 (0) | 0.72 (44) | 44 | 1.43 | 1.50 | |
| URE | 20.0 | 23 | 2.52 (58) + | 0.39 (09) + | 0.17 (4) + | 3.09 (71) + | 71 | 1.82 | 6.35 | 4.85 |
| NIC treatments | ||||||||||
| Water | 0 | 61 | 0.66 (40) | 0.07 (04) | 0.00 (0) | 0.72 (44) | 44 | 1.43 | 1.50 | |
| NIC | 0.0125 | 60 | 0.68 (41) - | 0.05 (03) - | 0.02 (1) - | 0.75 (45) - | 42 | 1.14 | 1.45 | -0.05 |
| NIC | 0.0250 | 60 | 0.65 (39) - | 0.03 (02) - | 0.00 (0) - | 0.68 (41) - | 41 | 1.29 | 1.40 | -0.10 |
| NIC | 0.0500 | 60 | 0.77 (46) - | 0.08 (05) - | 0.00 (0) - | 0.85 (51) - | 51 | 1.61 | 1.75 | 0.25 |
| #1 Assay∗ | ||||||||||
| Water | 0 | 35 | 0.54 (19) | 0.06 (02) | 0.00 (0) | 0.60 (21) | 21 | 1.29 | 1.25 | |
| NIC | 0.4560 | 99 | 0.38 (38) - | 0.07 (07) - | 0.03 (3) - | 0.48 (48) - | 47 | 1.64 | 0.95 | -0.25 |
| NIC | 1.9000 | 58 | 0.47 (27) - | 0.05 (03) - | 0.07 (4) - | 0.59 (34) - | 34 | 1.82 | 1.20 | -0.05 |
| NIC | 3.8000 | 69 | 0.36 (25) - | 0.06 (04) - | 0.00 (0) - | 0.42 (29) - | 28 | 1.61 | 0.85 | -0.40 |
| #2 Assay∗ | ||||||||||
| Water | 0 | 50 | 0.50 (25) - | 0.10 (05) | 0.04 (2) | 0.64 (32) | 32 | 1.66 | 1.30 | |
| NIC | 0.4560 | 60 | 0.33 (20) - | 0.08 (05) - | 0.02 (1) - | 0.43 (26) - | 25 | 1.64 | 0.85 | -0.45 |
| NIC | 1.9000 | 58 | 0.47 (27) - | 0.05 (03) - | 0.07 (4) - | 0.59 (34) - | 34 | 1.82 | 1.20 | -0.10 |
| NIC | 3.8000 | 60 | 0.37 (22) - | 0.05 (03) - | 0.00 (0) - | 0.42 (25) - | 24 | 1.42 | 0.80 | -0.50 |
Statistical diagnoses according to Frei and Würgler (1988) m: minimal risk multiplication factor for the assessment of negative results. For the final statistical diagnosis of all positive (+) and negative (-) results; the non-parametric Mann-Whitney and Wilcoxon U-test with significance levels α and β = 0.05 was used to exclude false positive or negative diagnoses [Frei and Würgler, 1995]. One side binomial test, significance levels α and β: significant results: + (α ≤ 0.05; no significant results: - (β ≤ 0.05).
ST: standard cross; HB: high bioactivation cross.
Clone frequencies per fly divided by the number of cells examined per fly (48,800) gives an estimate of formation frequencies per cell and per cell division in chronic exposure experiments [Frei and Würgler, 1995].∗In HB cross the NIC [11.4 mM] was lethal.
Genotoxic damage for ST and HB crosses with high [NIC]. Summary evaluation as not-genotoxic (-) or genotoxic (+) of each high NIC concentration treatment (NIC of 0.456 mM, 1.9 mM, 3.8 mM or 11.4 mM with no RES = 0.0 mM) and of the co-treatments (same NIC concentrations plus either 0.0004mM RES or 0.011mM RES) in the ST and the HB crosses. The co-treatment results were evaluated against the results for the ETOH dissolvent control for RES, the results for NIC (without RES) and the results for RES (without NIC). These comparisons were done with the non-parametric Mann-Whitney and Wilcoxon U-test P < 0.05 to provide additional information about which component of the co-treatment had the greatest effect.
| ST cross | Control or treatment in corresponding cross | HB cross | ||||||
|---|---|---|---|---|---|---|---|---|
| Nicotine (mM) | Resveratrol (mM) | Resveratrol (mM) | Nicotine (mM) | |||||
| 0.0 | 0.0004 | 0.011 | 0.0 | 0.0004 | 0.011 | |||
| 0.456 | - | - | + | EtOH | - | + | - | 0.456 |
| - | - | NIC | - | - | ||||
| - | - | RES | - | - | ||||
| 1.9 | - | + | + | EtOH | - | - | - | 1.9 |
| + | + | NIC | - | - | ||||
| + | + | RES | ↓ | - | ||||
| 3.8 | - | - | + | EtOH | - | + | - | 3.8 |
| - | - | NIC | + | + | ||||
| - | - | RES | - | + | ||||
| 11.4 | + | + | - | EtOH | - | 11.4 | ||
| + | ↓ | NIC | ||||||
| + | + | RES | - | |||||
NIC was compared against Milli-Q water to determine genotoxicity. + signifies an increase with P < 0.05 ↓ signifies a decrease with P < 0.05; - signifies that P > 0.05, signifies that treatment was lethal with no survivors.
Genotoxic damage for ST and HB crosses with low [NIC]. Summary evaluation as not-genotoxic (-) or genotoxic (+) of each low NIC concentration treatment (NIC of 0.0125 mM, 0.025 mM, or 0.05 mM with no RES = 0.0 mM) and of the co-treatments (same NIC concentrations plus 0.011mM RES) in the ST and the HB crosses. The co-treatment results were evaluated against the results for the ETOH dissolvent control for RES, the results for NIC (without RES) and the results for RES (without NIC). These comparisons were done with the non-parametric Mann-Whitney and Wilcoxon U-test P < 0.05 to provide additional information about which component of the co-treatment had the greatest effect.
| ST cross | Control or treatment in corresponding cross | HB cross | ||||
|---|---|---|---|---|---|---|
| Nicotine (mM) | Resveratrol (mM) | Resveratrol (mM) | Nicotine (mM) | |||
| 0.0 | 0.011 | 0.0 | 0.011 | |||
| 0.0125 | + | + | EtOH | - | - | 0.0125 |
| ↓ | NIC | - | ||||
| - | RES | - | ||||
| 0.0250 | - | + | EtOH | - | - | 0.0250 |
| + | NIC | - | ||||
| + | RES | - | ||||
| 0.0500 | - | - | EtOH | - | - | 0.0500 |
NIC was compared against Milli-Q water to determine genotoxicity. + signifies an increase with P < 0.05; ↓ signifies a decrease with P< 0.05; - signifies that P > 0.05.
Summary of results obtained in the standard (ST) and high bioactivation (HB) crosses of the Drosophila wing SMART after scoring marker-heterozygous flies (mwh +/+ flr, wild-type wings) treated with nicotine (NIC) at [0.0, 0.0125, 0.0250, 0.050, 0.456, 1.9, 3.8 and 11.4 mM] + resveratrol (RES) [0.0004 or 0.0110 mM]; ethanol (1%) as dissolvent control.
| Compound Cross | Number of flies | Spots per Fly (Number of Spots) Statistical Diagnosis | Mean | Clone formation | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Type | Small single spots | large single spots | Twin spots | Total spots | per 105 per cell | cells division | ||||
| (1-2 cells) | (>2 cells) | observed | control connected | |||||||
| m = 2 | m = 5 | m = 5 | m = 5 | |||||||
| NIC treatments + RES [0.0004 mM] | ||||||||||
| ST | ||||||||||
| EtOH | 1 % | 57 | 0.39 (022) | 0.09 (005) | 0.00 (000) | 0.47 (027) | 27 | 1.81 | 0.95 | |
| NIC+RES | 0.4560 | 33 | 0.61 (020) - | 0.06 (002) - | 0.00 (000) - | 0.67 (022) - | 22 | 1.45 | 1.35 | 0.40 |
| NIC+RES | 1.9000 | 22 | 0.77 (017) + | 0.27 (006) + | 0.00 (000) - | 1.05 (023) + | 23 | 1.87 | 2.15 | 1.15 |
| NIC+RES | 3.8000 | 38 | 0.42 (016) - | 0.05 (002) - | 0.00 (000) - | 0.47 (018) - | 16 | 1.06 | 0.85 | -0.10 |
| NIC+RES | 11.4000 | 13 | 0.92 (012) + | 0.38 (005) + | 0.00 (000) - | 1.31 (017) + | 17 | 2.47 | 2.70 | 1.70 |
| HB | ||||||||||
| EtOH | 1% | 35 | 0.34 (012) - | 0.09 (003) | 0.03 (001) | 0.46 (016) | 16 | 1.94 | 0.95 | |
| NIC+RES | 0.4560 | 64 | 0.36 (023) + | 0.11 (007) - | 0.00 (000) - | 0.47 (030) - | 29 | 2.21 | 0.95 | 0.00 |
| NIC+RES | 1.9000 | 49 | 0.29 (014) - | 0.08 (004) - | 0.02 (001) - | 0.39 (019) - | 18 | 2.33 | 0.75 | -0.20 |
| NIC+RES | 3.8000 | 78 | 0.59 (046) + | 0.05 (004) - | 0.03 (002) - | 0.67 (052) - | 52 | 1.63 | 1.35 | 0.45 |
| NIC+RES | 11.4000 | 10 | 0.40 (004) - | 0.00 (000) - | 0.00 (000) - | 0.40 (004) - | 04 | 1.25 | 0.80 | -0.10 |
| NIC treatments + RES [0.0110 mM] | ||||||||||
| ST | ||||||||||
| EtOH | 1 % | 57 | 0.39 (022) | 0.09 (005) | 0.00 (000) | 0.47 (027) | 27 | 1.81 | 0.95 | |
| NIC+RES | 0.4560 | 45 | 0.69 (031) + | 0.04 (002) - | 0.07 (004) - | 0.80 (036) + | 36 | 1.86 | 1.65 | 0.65 |
| NIC+RES | 1.9000 | 42 | 0.76 (032) + | 0.10 (004) - | 0.12 (005) + | 0.98 (041) + | 41 | 2.02 | 2.00 | 1.05 |
| NIC+RES | 3.8000 | 52 | 0.62 (032) - | 0.12 (006) - | 0.04 (002) - | 0.77 (040) + | 40 | 1.77 | 1.60 | 0.60 |
| NIC+RES | 11.4000 | 37 | 0.38 (014) - | 0.14 (005) - | 0.05 (002) - | 0.57 (021) - | 20 | 2.30 | 1.10 | 0.15 |
| HB∗ | ||||||||||
| EtOH | 1 % | 60 | 0.33 (020) - | 0.17 (010) - | 0.00 (000) - | 0.50 (030) - | 28 | 2.00 | 0.95 | |
| NIC+RES | 0.4560 | 60 | 0.37 (022) - | 0.10 (006) - | 0.02 (001) - | 0.48 (029) - | 29 | 1.97 | 1.00 | 0.05 |
| NIC+RES | 1.9000 | 61 | 0.34 (021) - | 0.10 (006) - | 0.05 (003) - | 0.49 (030) - | 29 | 2.03 | 1.00 | 0.00 |
| NIC+RES | 3.8000 | 60 | 0.45 (027) - | 0.22 (013) - | 0.00 (000) - | 0.67 (040) - | 40 | 2.42 | 1.35 | 0.40 |
| NIC treatments + RES [0.0110 mM] | ||||||||||
| ST | ||||||||||
| EtOH | 1 % | 60 | 0.45 (027) - | 0.15 (009) - | 0.05 (003) - | 0.65 (039) - | 38 | 2.34 | 1.30 | |
| NIC+RES | 0.0125 | 40 | 0.73 (029) + | 0.00 (000) - | 0.00 (000) - | 0.73 (029) - | 29 | 1.14 | 1.50 | 0.20 |
| NIC+RES | 0.0250 | 49 | 0.96 (047) + | 0.27 (013) - | 0.00 (000) - | 1.22 (060) + | 59 | 2.08 | 2.45 | 1.10 |
| NIC+RES | 0.0500 | 53 | 0.62 (033) - | 0.04 (002) - | 0.00 (000) - | 0.66 (035) - | 35 | 1.34 | 1.35 | -1.10 |
| EtOH | 1 % | 60 | 0.60 (036) - | 0.08 (005) - | 0.00 (000) - | 0.68 (041) - | 40 | 1.37 | 1.35 | |
| NIC+RES | 0.0125 | 67 | 0.54 (036) - | 0.00 (000) - | 0.04 (003) + | 0.58 (039) - | 39 | 1.54 | 1.20 | -0.15 |
| NIC+RES | 0.0250 | 59 | 0.68 (040) - | 0.07 (004) - | 0.00 (000) - | 0.75 (044) - | 44 | 1.36 | 1.55 | 0.15 |
| NIC+RES | 0.0500 | 57 | 0.63 (036) - | 0.05 (003) - | 0.00 (000) - | 0.68 (039) - | 39 | 1.33 | 1.40 | 0.05 |
Statistical diagnoses according to Frei and Würgler (1988) m: minimal risk multiplication factor for the assessment of negative results. For the final statistical diagnosis of all positive (+) and negative (-) results; the non-parametric Mann-Whitney and Wilcoxon U-test with significance levels α and β = 0.05 was used to exclude false positive or negative diagnoses [Frei and Würgler, 1995]. One side binomial test, significance levels α and β: significant results: + (α ≤ 0.05; no significant results: - (β ≤ 0.05).
ST: standard cross; HB: high bioactivation cross.
Clone frequencies per fly divided by the number of cells examined per fly (48,800) gives an estimate of formation frequencies per cell and per cell division in chronic exposure experiments [Frei and Würgler, 1995].∗In HB cross the NIC [11.4 mM] + RES [0.0110 mM] treatment was lethal.
Summary of results obtained in the standard (ST) and high bioactivation (HB) crosses of the Drosophila wing SMART after scoring marker-heterozygous flies (mwh +/+ flr, wild-type wings) treated with nicotine (NIC) at [0.0, 0.0125, 0.0250, 0.050, 0.456, 1.9, 3.8, 11.4 mM]; resveratrol (RES) at [0.0, 0.0004, 0.011 mM]; Milli-Q water and ethanol 1% as dissolvent controls.
| Compound Cross | Number of flies | Spots per Fly (Number of Spots) Statistical Diagnosis | Mean | Clone formation | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Type | Small single spots | large single spots | Twin spots | Total spots | per 105 per cell | Cells division | ||||
| (1-2 cells) | (>2 cells) | observed | control connected | |||||||
| m = 2 | m = 5 | m = 5 | m = 5 | |||||||
| RES [0.0004 mM] | ||||||||||
| Co-treatments NIC [mM]/RES [0.0004 mM] vs. RES [0.0004 mM] | ||||||||||
| RES | 0.0004 mM | 58 | 0.53 (031) | 0.07 (004) | 0.00 (0) | 0.60 (035) | 33 | 1.64 | 1.15 | |
| NIC | 0.456 + RES | 33 | 0.61 (020) - | 0.06 (002) - | 0.00 (0) - | 0.67 (022) - | 22 | 1.45 | 1.35 | 0.2 |
| NIC | 1.900 + RES | 22 | 0.77 (017) - | 0.27 (006) + | 0.00 (0) - | 1.05 (023) + | 23 | 1.87 | 2.15 | 1.0 |
| NIC | 3.800 + RES | 38 | 0.42 (016) - | 0.05 (002) - | 0.00 (0) - | 0.47 (018) - | 16 | 1.06 | 0.85 | -0.3 |
| NIC | 11.400 + RES | 13 | 0.92 (012) - | 0.38 (005) + | 0.00 (0) - | 1.31 (017) + | 17 | 2.47 | 2.70 | 1.5 |
| Co-treatments NIC [mM]/RES [0.0004 mM] vs. NIC | ||||||||||
| NIC | 0.456 mM | 38 | 0.68 (026) | 0.05 (002) | 0.00 (0) | 0.74 (028) | 28 | 1.54 | 1.50 | |
| NIC | 0.456 + RES | 33 | 0.61 (020) - | 0.06 (002) - | 0.00 (0) - | 0.67 (022) - | 22 | 1.45 | 1.35 | -0.15 |
| NIC | 1.900 | 46 | 0.57 (026) | 0.04 (002) | 0.02 (001) | 0.63 (029) | 28 | 1.57 | 1.25 | |
| NIC | 1.900 + RES | 22 | 0.77 (017) - | 0.27 (006) + | 0.00 (0) - | 1.05 (023) + | 23 | 1.87 | 2.25 | 1.0 |
| NIC | 3.800 | 32 | 0.62 (020) | 0.03 (001) | 0.03 (001) | 0.69 (022) | 22 | 1.45 | 1.40 | |
| NIC | 3.800 + RES | 38 | 0.42 (016) - | 0.05 (002) - | 0.00 (0) - | 0.47 (018) - | 16 | 1.06 | 0.85 | -0.55 |
| NIC | 11.400 | 22 | 1.27 (028) | 0.23 (005) | 0.05 (001) | 1.55 (034) | 34 | 1.71 | 3.15 | |
| NIC | 11.400 + RES | 13 | 0.92 (012) - | 0.38 (005) + | 0.00 (0) - | 1.31 (017) + | 17 | 2.47 | 2.65 | -0.5 |
| RES [0.011 mM] | ||||||||||
| Co-treatments NIC [mM]/RES [0.011 mM] vs. RES [0.011 mM] | ||||||||||
| RES | 0.011 mM | 58 | 0.47 (027) | 0.03 (002) | 0.07 (004) | 0.57 (033) | 32 | 1.84 | 1.15 | |
| NIC | 0.456 + RES | 45 | 0.69 (031) - | 0.04 (002) - | 0.07 (003) - | 0.80 (036) - | 36 | 1.86 | 1.65 | 0.5 |
| NIC | 1.900 + RES | 42 | 0.76 (032) + | 0.10 (004) - | 0.12 (005) - | 0.98 (041) + | 41 | 2.02 | 2.00 | 0.85 |
| NIC | 3.800 + RES | 52 | 0.62 (032) - | 0.12 (006) - | 0.04 (002) - | 0.77 (040) - | 40 | 1.77 | 1.60 | 0.45 |
| NIC | 11.400 + RES | 37 | 0.38 (014) - | 0.14 (005) + | 0.05 (002) - | 0.57 (021) - | 20 | 2.30 | 1.15 | 0.00 |
| o-treatments NIC [mM]/RES [0.011 mM] vs. NIC | ||||||||||
| NIC | 0.456 mM | 38 | 0.68 (026) | 0.05 (002) | 0.00 (0) | 0.74 (028) | 28 | 1.54 | 1.5 | |
| NIC | 0.456 + RES | 45 | 0.69 (031) - | 0.04 (002) - | 0.07 (003) - | 0.80 (036) - | 36 | 1.86 | 1.65 | 0.15 |
| NIC | 1.900 | 46 | 0.57 (026) | 0.04 (002) | 0.02 (001) | 0.63 (029) | 28 | 1.57 | 1.25 | |
| NIC | 1.900 + RES | 42 | 0.76 (032) - | 0.10 (004) - | 0.12 (005) + | 0.98 (041) + | 41 | 2.02 | 2.00 | 0.75 |
| NIC | 3.800 | 32 | 0.62 (020) | 0.03 (001) | 0.03 (001) | 0.69 (022) | 28 | 1.45 | 1.40 | |
| NIC | 3.800 + RES | 52 | 0.62 (032) - | 0.12 (006) - | 0.04 (002) - | 0.77 (040) - | 40 | 1.77 | 1.55 | 0.15 |
| NIC | 11.400 | 22 | 1.27 (028) | 0.23 (005) | 0.05 (001) | 1.55 (034) | 34 | 1.71 | 3.15 | |
| NIC | 11.400 + RES | 37 | 0.38 (014) ↓ | 0.14 (005) - | 0.05 (002) - | 0.57 (021) ↓ | 20 | 2.30 | 1.10 | -2.05 |
| Co-treatments NIC [mM]/RES [0.011 mM] vs. RES [0.011 mM] | ||||||||||
| RES | 0.011 mM | 99 | 0.58 (057) | 0.05 (005) | 0.04 (004) | 0.67 (066) | 65 | 1.58 | 1.35 | |
| NIC | 0.0125 + RES | 40 | 0.73 (029) - | 0.00 (000) - | 0.00 (000) - | 0.73 (029) - | 29 | 1.14 | 1.50 | 0.15 |
| NIC | 0.0250 + RES | 49 | 0.96 (047) + | 0.27 (013) - | 0.00 (000) - | 1.22 (060) + | 59 | 2.08 | 2.45 | 1.10 |
| NIC | 0.0500 + RES | 53 | 0.62 (033) - | 0.04 (002) - | 0.00 (000) - | 0.66 (035) - | 35 | 1.34 | 1.35 | 0.00 |
| Co-treatments NIC [mM]/RES [0.011 mM] vs. NIC | ||||||||||
| NIC | 0.0125 | 44 | 1.16 (051) | 0.43 (019) | 0.00 (000) | 1.59 (070) | 70 | 2.26 | 3.25 | |
| NIC | 0.0125 + RES | 40 | 0.73 (029) | 0.00 (000) | 0.00 (000) - | 0.73 (029) | 29 | 1.14 | 1.50 | -1.8 |
| 0.0250 | 41 | 0.66 (027) | 0.00 (000) | 0.02 (001) | 0.68 (028) | 28 | 1.21 | 1.40 | ||
| NIC | 0.0250 + RES | 49 | 0.96 (047) - | 0.27 (013) - | 0.00 (000) - | 1.22 (060) + | 59 | 2.08 | 2.45 | 1.05 |
| NIC | 0.050 | 21 | 0.67 (014) | 0.10 (002) | 0.05 (001) | 0.81 (017) | 17 | 1.47 | 1.66 | |
| NIC | 0.050 + RES | 53 | 0.62 (033) - | 0.04 (002) - | 0.00 (000) - | 0.66 (035) - | 35 | 1.34 | 1.35 | -0.31 |
| HB | ||||||||||
| RES 0.0004 mM | ||||||||||
| RES | 0.0004 | 87 | 0.52 (045) | 0.06 (005) | 0.01 (001) | 0.59 (051) | 51 | 1.84 | 1.20 | |
| NIC | 0.456 + RES | 64 | 0.36 (023) - | 0.11 (007) - | 0.00 (000) - | 0.47 (030) - | 29 | 2.21 | 0.95 | -0.25 |
| NIC | 1.900 + RES | 49 | 0.29 (014) ↓ | 0.08 (004) - | 0.02 (001) - | 0.39 (019) - | 18 | 2.33 | 0.75 | -0.45 |
| NIC | 3.800 + RES | 78 | 0.59 (046) - | 0.05 (004) - | 0.03 (002) - | 0.67 (052) - | 52 | 1.63 | 1.35 | 0.15 |
| NIC | 11.400 + RES | 10 | 0.40 (004) - | 0.00 (000) - | 0.00 (000) - | 0.40 (004) - | 04 | 1.25 | 0.80 | -0.40 |
| NIC | 0.456 | 99 | 0.38 (038) | 0.07 (007) | 0.03 (003) | 0.48(048) | 47 | 1.64 | 0.95 | |
| NIC | 0.456 + RES | 64 | 0.36 (023) - | 0.11 (007) - | 0.00 (000) - | 0.47 (030) - | 29 | 2.21 | 0.90 | -0.05 |
| NIC | 1.900 | 58 | 0.47 (027) | 0.05 (003) | 0.07 (004) | 0.59 (034) | 34 | 1.82 | 1.20 | |
| NIC | 1.900 + RES | 49 | 0.29 (014) - | 0.08 (004) - | 0.02 (001) - | 0.39 (019) - | 18 | 2.33 | 0.75 | -0.45 |
| NIC | 3.800 | 69 | 0.36 (025) | 0.06 (004) | 0.00 (000) | 0.42 (029) | 28 | 1.61 | 0.85 | |
| NIC | 3.800 + RES | 78 | 0.59 (046) + | 0.05 (004) - | 0.03 (002) - | 0.67 (052) + | 52 | 1.63 | 1.40 | 0.55 |
| RES 0.011 mM | ||||||||||
| RES | 0.011 | 59 | 0.36 (021) | 0.02 (001) | 0.02 (001) | 0.39 (023) | 23 | 1.43 | 0.80 | |
| NIC | 0.456 + RES | 60 | 0.37 (022) - | 0.10 (006) - | 0.02 (001) - | 0.48 (029) - | 29 | 1.97 | 1.00 | 0.20 |
| NIC | 1.900 + RES | 60 | 0.34 (021) - | 0.10 (006) - | 0.05 (003) - | 0.49 (030) - | 29 | 2.03 | 1.00 | 0.20 |
| NIC | 3.800 + RES | 60 | 0.45 (027) - | 0.22 (013) + | 0.00 (000) - | 0.67 (040) - | 40 | 2.42 | 1.35 | 0.55 |
| Co-treatments NIC [mM]/RES [0.011 mM] vs. NIC | ||||||||||
| NIC | 0.456 | 60 | 0.33 (020) | 0.08 (005) | 0.02 (001) | 0.43 (026) | 25 | 1.64 | 0.85 | |
| NIC | 0.456 + RES | 60 | 0.37 (022) - | 0.10 (006) - | 0.02 (001) - | 0.48 (029) - | 29 | 1.97 | 1.00 | 0.15 |
| NIC | 1.900 | 58 | 0.47 (027) | 0.05 (003) | 0.07 (004) | 0.59 (034) | 34 | 1.82 | 1.2 | |
| NIC | 1.900 + RES | 60 | 0.34 (021) - | 0.10 (006) - | 0.05 (003) - | 0.49 (030) - | 29 | 2.03 | 1.0 | 0.20 |
| NIC | 1.900 + RES | 60 | 0.34 (021) - | 0.10 (006) - | 0.05 (003) - | 0.49 (030) - | 29 | 2.03 | 1.0 | 0.20 |
| NIC | 1.900 + RES | 60 | 0.34 (021) - | 0.10 (006) - | 0.05 (003) - | 0.49 (030) - | 29 | 2.03 | 1.0 | 0.20 |
| NIC | 3.800 + RES | 60 | 0.45 (027) - | 0.22 (013) + | 0.00 (000) - | 0.67 (040) + | 40 | 2.42 | 1.35 | 0.55 |
| Co-treatments NIC [mM]/RES [0.011 mM] vs. RES [0.011 mM] | ||||||||||
| RES | 0.011 mM | 60 | 0.73 (044) | 0.07 (004) | 0.02 (001) | 0.82 (049) | 48 | 1.56 | 1.65 | |
| NIC | 0.0125 + RES | 67 | 0.54 (036) - | 0.00 (000) - | 0.04 (003)- | 0.58 (039) - | 39 | 1.54 | 1.20 | -0.45 |
| NIC | 0.0250 + RES | 59 | 0.68 (040) - | 0.07 (004) - | 0.00 (000) - | 0.75 (044) - | 44 | 1.36 | 1.55 | -0.10 |
| NIC | 0.0500 + RES | 57 | 0.63 (036) - | 0.05 (003) - | 0.00 (000) - | 0.68 (039) - | 39 | 1.33 | 1.40 | -0.25 |
| Co-treatments NIC [mM]/RES [0.011 mM] vs. NIC | ||||||||||
| NIC | 0.0125 | 60 | 0.68 (041) | 0.05 (003) | 0.02 (001) | 0.75 (045) | 42 | 1.14 | 1.45 | |
| NIC | 0.0125 + RES | 67 | 0.54 (036) - | 0.00 (000) - | 0.04 (003)- | 0.58 (039) - | 39 | 1.54 | 1.2 | -0.25 |
| NIC | 0.0250 | 60 | 0.65 (039) | 0.03 (002) | 0.00 (000) | 0.68 (041) - | 41 | 1.29 | 1.4 | |
| NIC | 0.0250 + RES | 59 | 0.68 (040) - | 0.07 (004) - | 0.00 (000) - | 0.75 (044) - | 44 | 1.36 | 1.55 | 0.15 |
| NIC | 0.050 | 60 | 0.77 (046) | 0.08 (005) | 0.00 (000) | 0.85 (051) - | 51 | 1.61 | 1.75 | |
| NIC | 0.050 + RES | 57 | 0.63 (036) - | 0.05 (003) - | 0.00 (000) - | 0.68 (039) - | 39 | 1.33 | 1.4 | -0.35 |
Statistical diagnoses according to Frei and Würgler (1988) m: minimal risk multiplication factor for the assessment of negative results. For the final statistical diagnosis of all positive (+) and negative (-) results; (↓) significant decrease; the non-parametric Mann-Whitney and Wilcoxon U-test with significance levels α and β = 0.05 was used to exclude false positive or negative diagnoses [Frei and Würgler, 1995]. One side binomial test, significance levels α and β: significative results: + (α ≤ 0.05; no significant results: - (β ≤ 0.05).
ST: standard cross; HB: high bioactivation cross.
Clone frequencies per fly divided by the number of cells examined per fly (48,800) gives an estimate of formation frequencies per cell and per cell division in chronic exposure experiments [Frei and Würgler, 1995].